Torisel

Kidney Neoplasms
Treatment
2 FDA approvals
12 Active Studies for Torisel

What is Torisel

TemsirolimusThe Generic name of this drug
Treatment SummaryTemsirolimus, sold under the brand name Torisel, is an medication used to treat kidney cancer. It was developed by Wyeth Pharmaceuticals and approved by the FDA in 2007 and the European Medicines Agency in November of the same year.
Toriselis the brand name
image of different drug pills on a surface
Torisel Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Torisel
Temsirolimus
2007
5

Approved as Treatment by the FDA

Temsirolimus, otherwise called Torisel, is approved by the FDA for 2 uses including Advanced Renal Cell Carcinoma (aRCC) and Kidney Neoplasms .
Advanced Renal Cell Carcinoma (aRCC)
Kidney Neoplasms

Effectiveness

How Torisel works in the bodyTemsirolimus stops cell division by blocking a protein called mTOR. This protein helps control cell division and when it is blocked, cells can't divide. Temsirolimus also blocks two other proteins, p70S6k and S6 ribosomal protein, which are part of the PI3 Kinase/AKT pathway. Finally, it reduces the levels of two substances called hypoxia-inducible factors (HIF-1 and HIF-2 alpha) and a protein responsible for blood vessel growth (vascular endothelial growth factor).

When to interrupt dosage

The suggested measure of Torisel is contingent upon the diagnosed circumstance. The dosage likewise changes as indicated by the approach of delivery featured in the table beneath.
Condition
Dosage
Administration
Kidney Neoplasms
, 30.0 mg, 25.0 mg/mL
Intravenous, , Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Kit - Intravenous

Warnings

Torisel has one contraindication and should not be utilized while enduring the conditions laid out in the subsequent table.Torisel Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Torisel.
Common Torisel Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Temsirolimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Temsirolimus.
Abetimus
Major
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Acteoside.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Temsirolimus.
Torisel Toxicity & Overdose RiskTemsirolimus can be given to cancer patients in doses of up to 220mg/m2. However, higher doses can increase the risk of serious problems such as blood clots, punctured intestines, lung disease, seizures, and mental health issues.
image of a doctor in a lab doing drug, clinical research

Torisel Novel Uses: Which Conditions Have a Clinical Trial Featuring Torisel?

15 active trials are being conducted to analyze the potential of Torisel to treat Advanced Renal Cell Carcinoma (aRCC).
Condition
Clinical Trials
Trial Phases
Kidney Neoplasms
12 Actively Recruiting
Not Applicable, Phase 2, Phase 1

Torisel Reviews: What are patients saying about Torisel?

4.7Patient Review
2/6/2008
Torisel for Cancer Involving the Kidney Cells
I was diagnosed with renal cell carcinoma three years ago and had one kidney removed. I've been on Torisel for three months now, and it has effectively stopped the growth of the tumor and even caused a slight reduction in the active area. The side effects are definitely worth it considering what could happen if I wasn't taking this medication.
4.7Patient Review
2/22/2009
Torisel for Cancer Involving the Kidney Cells
Torisel has been a godsend. I've been taking it for nine months with few negative side effects. My tumors have stopped growing, and I'm feeling much better overall.
4.7Patient Review
12/31/2007
Torisel for Cancer Involving the Kidney Cells
Torisel has been great for me. I haven't experienced too many side effects, and my tumors have stayed the same size according to my CT scan.
4Patient Review
2/2/2009
Torisel for Cancer Involving the Kidney Cells
So far, I've had good results with this treatment. My tumors were growing and now they're stable. I don't have any new ones either. The worst side effect is the fatigue after taking Benedryl as a pre-medication.
4Patient Review
12/4/2008
Torisel for Cancer Involving the Kidney Cells
I've completed nine rounds of this treatment and the only notable side effect has been a change in taste. As for efficacy, my most recent scan showed no change in cancer size.
3.7Patient Review
8/7/2009
Torisel for Cancer Involving the Kidney Cells
I've had seven treatments so far. The first CT scan was taken shortly after starting treatment. I have chromophobe kidney cancer that has metastasized to my bones. The side effects from Sutent were too difficult for me to handle, so I dropped the dose and eventually stopped taking it altogether. I switched to Torisel and while the skin rashes are bad, the rest of the side effects are tolerable.
3.3Patient Review
6/12/2009
Torisel for Cancer Involving the Kidney Cells
I've now received 37 treatments. I haven't had any bad reactions, just changes to my taste buds. Everything tastes bad now! My cancer is still growing but it's slowed down. I have renal cell carcinoma in 5 spots. I just finished radiation treatment for quality of life issues and now I can walk again.
3Patient Review
2/4/2009
Torisel for Cancer Involving the Kidney Cells
Torisel was easy use and significantly reduced my tumors after 8 treatments. Then it stopped working.
3Patient Review
3/24/2010
Torisel for Cancer Involving the Kidney Cells
Today was my wife's 14th treatment of Torisel, and we are scheduled for our second CT/scan while on this drug. The first scan was promising after taking both Sutent and Nexavar with little positive results. Since she has been on Torisel there have been fatigue after each dose and a blood transfusion because of the effect of Torisel reducing blood counts. Thankfully no mouth sores so far
2.3Patient Review
2/15/2012
Torisel for Cancer Involving the Kidney Cells
This treatment caused extensive skin lesions and itching.
1.7Patient Review
10/8/2007
Torisel for Cancer Involving the Kidney Cells
My dad started this treatment recently for his stage 4 renal cell carcinoma. He's had a tough year, and this is the third treatment he's tried (after Nexavar and Sutent). So far he's only had one treatment, so I'll update this review when I know more.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about torisel

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is Torisel administered?

"Use an infusion pump to deliver TORISEL intravenously over 30-60 minutes once a week."

Answered by AI

Is temsirolimus a chemotherapy?

"The drug Temsirolimus is also known by the brand name Torisel. Your healthcare professional may use the brand name when referencing the generic drug."

Answered by AI

How is temsirolimus administered?

"Temsirolimus is a prescription medication used to treat a certain type of kidney cancer. It comes as a solution that is injected into a vein over 30-60 minutes. Temsirolimus is usually given once a week by a doctor or nurse in a doctor's office or infusion center."

Answered by AI

What is Torisel used for?

"Torisel is a cancer medicine that slows the growth and spread of cancer cells in the body. It is used to treat renal cell carcinoma, a type of cancer that affects the kidneys. Torisel may also be used for other purposes not listed in this medication guide."

Answered by AI

Clinical Trials for Torisel

Image of City of Hope Medical Center in Duarte, United States.

RP2 + Tivozanib for Kidney Cancer

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing, spreading, or getting worse (progressive) after receiving immunotherapy with immune checkpoint inhibitors (ICIs). RP2 is a herpes simplex virus (a viral infection commonly known as the "cold sore virus") that has been changed to infect and destroy tumor cells and to activate (turn on) the human immune system to attack the tumor cells. Tivozanib hydrochloride blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Tivozanib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Giving RP2 and tivozanib may be safe, tolerable, and/or effective in treating patients with metastatic renal cell cancer that has progressed after receiving immunotherapy with ICIs.
Phase 2
Waitlist Available
City of Hope Medical Center (+1 Sites)Charles B Nguyen
Image of Columbia University Irving Medical Center in New York, United States.

XL092 + Nivolumab for Kidney Cancer

18+
All Sexes
New York, NY
The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of zanzalintinib (XL092) alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
Phase 2
Recruiting
Columbia University Irving Medical Center (+1 Sites)Karie Runcie, MDExelixis
Image of City of Hope Medical Center in Duarte, United States.

CBM588 + Nivolumab + Ipilimumab for Advanced Kidney Cancer

18+
All Sexes
Duarte, CA
This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). CBM588 is a live biotherapeutic that may help improve the effects of immunotherapy. Nivolumab and ipilimumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread by enhancing the ability of the body's immune cells to attack tumor cells. CBM588 in combination with nivolumab and ipilimumab may be safe, tolerable, and/or effective in treating patients with advanced stage kidney cancer.
Phase 1
Recruiting
City of Hope Medical CenterAlex Chehrazi-Raffle, MDOsel, Inc.
Image of Mayo Clinic in Florida in Jacksonville, United States.

Nivolumab for Cancer

18+
All Sexes
Jacksonville, FL
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.
Phase 2
Recruiting
Mayo Clinic in FloridaRoxana S. Dronca, M.D.
Have you considered Torisel clinical trials? We made a collection of clinical trials featuring Torisel, we think they might fit your search criteria.Go to Trials
Have you considered Torisel clinical trials? We made a collection of clinical trials featuring Torisel, we think they might fit your search criteria.Go to Trials
Image of University of California, San Francisco in San Francisco, United States.

Predictive Marker Analysis for Prostate Cancer

18+
Male
San Francisco, CA
This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will be enrolled in into one of several parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted Therapy/Investigational therapeutic, (E) DNA damage response pathway, (F) Aggressive variant disease, (G1) Castration-sensitive ADT naïve and ADT \< 3 months), or (G2) Castration-sensitive pre-treated with sub-optimal PSA nadir \>0.2 ng/ml, (R) metastatic renal cell carcinoma and metastatic and (U) urothelial carcinoma.
Waitlist Available
Has No Placebo
University of California, San FranciscoRahul Aggarwal, MDStrata Oncology
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security